These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 35404282)

  • 1. Retaining Participants in Longitudinal Studies of Alzheimer's Disease.
    Gabel M; Bollinger RM; Coble DW; Grill JD; Edwards DF; Lingler JH; Chin E; Stark SL
    J Alzheimers Dis; 2022; 87(2):945-955. PubMed ID: 35404282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retention of Study Partners in Longitudinal Studies of Alzheimer Disease.
    Bollinger RM; Gabel M; Coble DW; Chen SW; Keleman AA; Doralus J; Chin E; Lingler JH; Grill JD; Stark SL; Edwards DF
    J Alzheimers Dis; 2023; 94(1):189-199. PubMed ID: 37212114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experiences of and recommendations on clinical trial design in Alzheimer's disease from the participant's point of view: a mixed-methods study in two clinical trial centers in the Netherlands.
    Ottenhoff L; Vijverberg EGB; Visser LNC; Verijp M; Prins ND; Van der Flier WM; Sikkes SAM
    Alzheimers Res Ther; 2023 Apr; 15(1):72. PubMed ID: 37016435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mild cognitive impairment in Parkinson's disease versus Alzheimer's disease.
    Besser LM; Litvan I; Monsell SE; Mock C; Weintraub S; Zhou XH; Kukull W
    Parkinsonism Relat Disord; 2016 Jun; 27():54-60. PubMed ID: 27089852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer's Disease and At-risk Individuals.
    Keine D; Walker JQ; Kennedy BK; Sabbagh MN
    Curr Aging Sci; 2018; 11(3):173-181. PubMed ID: 30338750
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Independent effects of white matter hyperintensities on cognitive, neuropsychiatric, and functional decline: a longitudinal investigation using the National Alzheimer's Coordinating Center Uniform Data Set.
    Puzo C; Labriola C; Sugarman MA; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Stein TD; Kowall NW; McKee AC; Mez J; Killiany RJ; Stern RA; Alosco ML
    Alzheimers Res Ther; 2019 Jul; 11(1):64. PubMed ID: 31351489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimating Alzheimer's Disease Progression Rates from Normal Cognition Through Mild Cognitive Impairment and Stages of Dementia.
    Davis M; O Connell T; Johnson S; Cline S; Merikle E; Martenyi F; Simpson K
    Curr Alzheimer Res; 2018; 15(8):777-788. PubMed ID: 29357799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of Plasma Neurofilament Light Chain and Mini-Mental State Examination Score Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease within 5 Years.
    Darmanthé N; Tabatabaei-Jafari H; Cherbuin N;
    J Alzheimers Dis; 2021; 82(3):951-964. PubMed ID: 34120902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
    Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
    J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychotropic Medication and Cognitive, Functional, and Neuropsychiatric Outcomes in Alzheimer's Disease (AD).
    Oh ES; Rosenberg PB; Rattinger GB; Stuart EA; Lyketsos CG; Leoutsakos JS
    J Am Geriatr Soc; 2021 Apr; 69(4):955-963. PubMed ID: 33382921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer's Disease Biomarker Research? A Qualitative Vignette Analysis.
    Ketchum FB; Erickson CM; Chin NA; Gleason CE; Lambrou NH; Benton SF; Clark LR
    J Alzheimers Dis; 2022; 87(3):1167-1179. PubMed ID: 35466937
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anosognosia Is an Independent Predictor of Conversion From Mild Cognitive Impairment to Alzheimer's Disease and Is Associated With Reduced Brain Metabolism.
    Gerretsen P; Chung JK; Shah P; Plitman E; Iwata Y; Caravaggio F; Nakajima S; Pollock BG; Graff-Guerrero A;
    J Clin Psychiatry; 2017; 78(9):e1187-e1196. PubMed ID: 29022655
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer's dementia.
    Zhao A; Li Y; Yan Y; Qiu Y; Li B; Xu W; Wang Y; Liu J; Deng Y
    Transl Neurodegener; 2020 Aug; 9(1):30. PubMed ID: 32741361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease risk factors as mediators of subjective memory impairment and objective memory decline: protocol for a construct-level replication analysis.
    Hill NL; Mogle J
    BMC Geriatr; 2018 Oct; 18(1):260. PubMed ID: 30373526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuropsychological Contribution to Predict Conversion to Dementia in Patients with Mild Cognitive Impairment Due to Alzheimer's Disease.
    Silva D; Cardoso S; Guerreiro M; Maroco J; Mendes T; Alves L; Nogueira J; Baldeiras I; Santana I; de Mendonça A
    J Alzheimers Dis; 2020; 74(3):785-796. PubMed ID: 32083585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal Neuropsychological Outcome in Taiwanese Alzheimer's Disease Patients Treated with Medication.
    Yang YH; Wu MN; Chou PS; Su HC; Lin SH; Sung PS
    Curr Alzheimer Res; 2018 Mar; 15(5):474-481. PubMed ID: 29032750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stages of Objective Memory Impairment Predict Alzheimer's Disease Neuropathology: Comparison with the Clinical Dementia Rating Scale-Sum of Boxes.
    Grober E; Qi Q; Kuo L; Hassenstab J; Perrin RJ; Lipton RB
    J Alzheimers Dis; 2021; 80(1):185-195. PubMed ID: 33492286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Revised criteria for mild cognitive impairment may compromise the diagnosis of Alzheimer disease dementia.
    Morris JC
    Arch Neurol; 2012 Jun; 69(6):700-8. PubMed ID: 22312163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Goal-oriented cognitive rehabilitation for early-stage Alzheimer's and related dementias: the GREAT RCT.
    Clare L; Kudlicka A; Oyebode JR; Jones RW; Bayer A; Leroi I; Kopelman M; James IA; Culverwell A; Pool J; Brand A; Henderson C; Hoare Z; Knapp M; Morgan-Trimmer S; Burns A; Corbett A; Whitaker R; Woods B
    Health Technol Assess; 2019 Mar; 23(10):1-242. PubMed ID: 30879470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.